Crossmark

R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma

Published Online: 2016-08-03

Published Print: 2016-10

Authors

Laribi, Kamel

Denizon, Nathalie

Bolle, Delphine

Truong, Catherine

Besançon, Anne

Sandrini, Jeremy

Anghel, Andreaa

Farhi, Jonathan

Ghnaya, Habib

Baugier de Materre, Alix
License Information

Text and Data Mining valid from 2016-08-03

Version of Record valid from 2016-08-03
More Information

Article History

Received: 24 March 2016

Accepted: 23 July 2016

First Online: 3 August 2016

Compliance with Ethical Standards

:

: Dr. Laribi has received grant and/or research support from Hospira, Roche, Teva, Janssen-Cilag, Mundipharma, Novartis, and honoraria from Amgen and Novartis.Dr. Denizon has received grant and/or research support from Roche and Novartis.

Document is current